Endologix, Inc. ( ELGX)

Stephens Inc. Fall Investment Conference

November 15, 2011 11:30 AM ET

Executives

John McDermott – President and CEO

Presentation

Unidentified Analyst

Good morning everyone. Thank you for joining us in the courtesy (ph) for our next presentation we’re honored to have John McDermott, the President and Chief Executive Officer of Endologix with us here today. Endologix is one of our top techs in a Medtech’s face. We have the stock rate overweight with a $14 price target. And you’re going to find that this is definitely the most prolific growth portfolios in the interventional space today and clearly, one of the top 10 growers in Medtech across our 100 plus company universe.

So, with that, I’ll turn it over to John.

John McDermott

Thanks Chris, good morning. John McDermott, I’m the CEO of Endologix. And I’ll take you through our company here. These are our Safe Harbor Statements.

Just briefly executive summary, this is a fast growing medical technology company located in Irvine California. We repair abdominal aortic aneurysms with a very differentiated technology and have a promising pipeline, and I’ll take you through all those details.

The company has also grown nicely. We just reported our third quarter revenue growth of 25%, better than 33% in the US and we’ll go through these markets and the technologies here in detail.

So, this illustrates what we do. The traditional way to repair an aneurysm is the picture on the right, open surgical repair where you get an open abdominal incision from just below your sternum down below your belly button. Your aorta lay is very deep in your torso, it actually is almost laying on your backbone when you lay down. So, it’s a difficult, very invasive procedure.

If you liked this article you might like

Endologix Poised for a Potentially Volatile Breakout

5 Stocks Trending Close to Major Breakouts

5 Stocks Set for Explosive Breakouts

These 5 Stocks Under $10 Could Make You a Lot of Money

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains